Director Evelyn D'An filed a Form 4 with the SEC on November 6, 2026, disclosing the grant of a stock option to purchase 5,000 shares of Matinas BioPharma Holdings, Inc. common stock under the company's 2025 Equity Incentive Plan.

Key Highlights

  • Grant date: November 6, 2026, the date of earliest transaction reported in the filing.
  • Option size: 5,000 shares of common stock (par value $0.0001 per share) acquired via a stock option (right to buy), transaction code A.
  • Exercise price: $1.16 per share, with an expiration date of November 6, 2036.
  • Vesting terms: The option vests in full on the earlier of the one-year anniversary of the grant date or a "Change in Control" as defined by the 2025 Equity Incentive Plan, subject to continued service.
  • Price paid: $0, as reported in the filing for the derivative security price.
  • Resulting ownership: 5,000 derivative securities beneficially owned following the reported transaction, held directly.

Director D'An Option Grant Details at Matinas BioPharma

According to the Form 4 filed with the SEC, Evelyn D'An, a director of Matinas BioPharma Holdings, Inc. (NYSE American:MTNB), was granted a stock option to purchase 5,000 shares of the issuer's common stock on November 6, 2026. The filing identifies the grant as made pursuant to the issuer's 2025 Equity Incentive Plan. The option carries an exercise price of $1.16 per share and is set to expire on November 6, 2036.

The filing discloses that the option was acquired at a price of $0 and will vest in full upon the earlier of two conditions: the one-year anniversary of the grant date, or a "Change in Control" as defined by the Plan. In either case, vesting is subject to the reporting person's continued service through the applicable vesting date. The form was signed by Jerome D. Jabbour as attorney-in-fact for Evelyn D'An on November 6, 2026.

Following the reported transaction, D'An beneficially owns 5,000 derivative securities directly, with no non-derivative securities reported in Table I of the filing. The filing was made by one reporting person and is not noted as an amendment to a prior filing.

What Was Disclosed

The filing reports a single stock option grant of 5,000 shares to director Evelyn D'An at an exercise price of $1.16, expiring November 6, 2036, issued under Matinas BioPharma's 2025 Equity Incentive Plan with cliff vesting at one year or upon a Change in Control.